Rallybio Profit Margin

Rallybio (RLYB) currently reports a profit margin of 7051.24% as of June 2026. That compares with -5473.32% in the prior-year period — up 228.8% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Rallybio's profit margin history and peer comparisons.

Rallybio's profit margin increased from -5473.32% to 7051.24% — a 228.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rallybio's profit margin of 7051.24% is higher than the Healthcare sector average of 14.34%. That is roughly 49055.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Rallybio's current 7051.24% should be judged against Healthcare norms (sector average: 14.34%) and against RLYB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 7051.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Rallybio, and consider following RLYB for alerts when major investors trade the stock.